Loading...
Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study
Hall, M Bertelli, G Li, L Green, C Chan, S Yeoh, CC Hasan, Jurjees Jones, R Ograbek, A Perren, TJ
Hall, M
Bertelli, G
Li, L
Green, C
Chan, S
Yeoh, CC
Hasan, Jurjees
Jones, R
Ograbek, A
Perren, TJ
Citations
Altmetric:
Abstract
OBJECTIVE:
Two randomized phase III trials demonstrated the efficacy and safety of combining bevacizumab with front-line carboplatin/paclitaxel for advanced ovarian cancer. The OSCAR (NCT01863693) study assessed the impact of front-line bevacizumab-containing therapy on safety and oncologic outcomes in patients with advanced ovarian cancer in the UK.
METHODS:
Between May 2013 and April 2015, patients with high-risk stage IIIB-IV advanced ovarian cancer received bevacizumab (7.5 or 15?mg/kg every 3 weeks, typically for ²12 months, per UK clinical practice) combined with front-line chemotherapy, with bevacizumab continued as maintenance therapy. Co-primary endpoints were progression-free survival and safety (NCI-CTCAE v4.0). Patients were evaluated per standard practice/physician's discretion.
RESULTS:
A total of 299 patients received bevacizumab-containing therapy. The median age was 64 years (range 31-83); 80 patients (27%) were aged ³70 years. Surgical interventions were primary debulking in 21%, interval debulking in 36%, and none in 43%. Most patients (93%) received bevacizumab 7.5?mg/kg with carboplatin/paclitaxel. Median duration of bevacizumab was 10.5 months(range <0.1-41.4); bevacizumab and chemotherapy were given in combination for a median of three cycles (range 1-10). Median progression-free survival was 15.4 (95%?CI 14.5 to 16.9) months. Subgroup analyses according to prior surgery showed median progression-free survival of 20.8, 16.1, and 13.6 months in patients with primary debulking, interval debulking, and no surgery, respectively. Median progression-free survival was 16.1 vs 14.8 months in patients aged <70 versus ³70 years, respectively. The 1-year overall survival rate was 94%. Grade 3/4 adverse events occurred in 54% of patients, the most common being hypertension (16%) and neutropenia (5%). Thirty-five patients (12%) discontinued bevacizumab for toxicity (most often for proteinuria (2%)).
CONCLUSIONS:
Median progression-free survival in this study was similar to that in the high-risk subgroup of the ICON7 phase III trial. Median progression-free survival was shortest in patients who did not undergo surgery.
Affiliation
Description
Date
2019
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 333.02 KB
Keywords
Type
Article
Citation
Hall M, Bertelli G, Li L, Green C, Chan S, Yeoh CC, et al. Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. Int J Gynecol Cancer. 2019.